All In Biotech

Drug Trial Radar · NCT03452228

Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

A Phase 2, Randomized, Placebo-Controlled Study of Safety and Efficacy, Following Repeat-Dose Administration of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

Last checked: Nov 20, 2026Latest source record: Feb 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

52

Actual

Start

Jun 7, 2018

Primary completion

Dec 17, 2019

Study completion Jul 23, 2020

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Mar 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to determine the change in Triglyceride (TG) levels following 12 weeks of repeated Intravenous (IV) doses of evinacumab.

Conditions

  • Severe Hypertriglyceridemia (sHTG)

Interventions

  • evinacumabDrug

    Administered by Intravenous (IV)

  • PlaceboDrug

    Administered by Intravenous (IV)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Fasting Triglycerides (TG) Level Following 12 Weeks of Repeated IV Doses of Evinacumab in Actual Cohort 3 ParticipantsTime frame: Participants randomized to evinacumab: Week 0 corresponds to Baseline and 12 weeks treatment corresponds to Week 12 of the DBTP; Participants randomized to placebo: Week 12 corresponds to Baseline and 12 weeks treatment corresponds to Week 24 of the SBTP

Locations

17 sites in 4 countries. Site status is shown where the registry gives one.

  • Regeneron Research Facility

    Boca Raton, Florida

  • Regeneron Research Facility

    Atlanta, Georgia

  • Regeneron Research Facility

    Kansas City, Kansas

  • Regeneron Research Facility

    New York, New York

  • Regeneron Research Facility

    Philadelphia, Pennsylvania

  • Regeneron Research Facility

    Pittsburgh, Pennsylvania

  • Regeneron Research Facility

    Dallas, Texas

  • Regeneron Research Facility

    Houston, Texas

  • Regeneron Research Facility

    Milwaukee, Wisconsin

  • Regeneron Research Facility

    Chicoutimi, Quebec, Canada

  • Regeneron Research Facility

    Québec, Quebec, Canada

  • Regeneron Research Facility

    Rome, Italy

  • Regeneron Research Facility

    Naples, Campania, Italy

  • Regeneron Research Facility

    Birmingham, United Kingdom

  • Regeneron Research Facility

    London, United Kingdom

  • Regeneron Research Facility

    London, United Kingdom

  • Regeneron Research Facility

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.